Jie Mei1,2,3, Yu-Hao Tang1,2,3, Wei Wei1,2,3, Ming Shi1,2,3, Lie Zheng2,3,4, Shao-Hua Li1,2,3, Rong-Ping Guo1,2,3. 1. Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Guangzhou, China. 3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 4. Department of Medical Imaging, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Abstract
BACKGROUND: Lenvatinib combined with programmed cell death protein-1 (PD-1) inhibitors has resulted in good survival outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatic artery infusion chemotherapy (HAIC) has also attracted attention due to its high response rates and favorable survival for advanced HCC patients. The present study aimed to compare the efficacy of HAIC combined with PD-1 inhibitors plus lenvatinib (HPL) and PD-1 inhibitors plus lenvatinib (PL) in patients with advanced HCC. METHODS: Between July 2018 and December 2019, patients diagnosed with advanced HCC who initially received HPL or PL treatment were reviewed for eligibility. Efficacy was evaluated according to tumor response and survival. RESULTS: In total, 70 patients met the criteria and were included in the present study, and they were divided into the HPL group (n = 45) and PL group (n = 25). The overall response rate (40.0 vs. 16.0%, respectively; p = 0.038) and disease control rate (77.6 vs. 44.0%, respectively; p < 0.001) were higher in the HPL group than in the PL group. The median overall survival was 15.9 months in the HPL group and 8.6 months in the PL group (p = 0.0015; HR = 0.6; 95% CI 0.43-0.83). The median progression-free survival was 8.8 months in the HPL group and 5.4 months in the PL group (p = 0.0320; HR = 0.74; 95% CI 0.55-0.98). CONCLUSION: Compared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.
BACKGROUND: Lenvatinib combined with programmed cell death protein-1 (PD-1) inhibitors has resulted in good survival outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatic artery infusion chemotherapy (HAIC) has also attracted attention due to its high response rates and favorable survival for advanced HCC patients. The present study aimed to compare the efficacy of HAIC combined with PD-1 inhibitors plus lenvatinib (HPL) and PD-1 inhibitors plus lenvatinib (PL) in patients with advanced HCC. METHODS: Between July 2018 and December 2019, patients diagnosed with advanced HCC who initially received HPL or PL treatment were reviewed for eligibility. Efficacy was evaluated according to tumor response and survival. RESULTS: In total, 70 patients met the criteria and were included in the present study, and they were divided into the HPL group (n = 45) and PL group (n = 25). The overall response rate (40.0 vs. 16.0%, respectively; p = 0.038) and disease control rate (77.6 vs. 44.0%, respectively; p < 0.001) were higher in the HPL group than in the PL group. The median overall survival was 15.9 months in the HPL group and 8.6 months in the PL group (p = 0.0015; HR = 0.6; 95% CI 0.43-0.83). The median progression-free survival was 8.8 months in the HPL group and 5.4 months in the PL group (p = 0.0320; HR = 0.74; 95% CI 0.55-0.98). CONCLUSION: Compared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.
Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316
Authors: Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M Llovet Journal: J Clin Oncol Date: 2020-07-27 Impact factor: 44.544